
    
      The treatment protocol consisted of monthly 12 mg/m2 MITO intravenous infusions for 6 months
      followed by 3 additional treatments every 3 months. Neurological assessment including the
      determination of the Expanded Disability Status Scale (EDSS) score was performed every 3
      months and during relapses. Orbital, brain and spinal cord MRI was performed at baseline, 3,
      6, 12, 18, and 24 months. Visual evoked potentials and ophthalmologic evaluations were
      performed at baseline and annually.
    
  